EC approves Gilead's Stribild

Gilead Sciences Inc. (NASDAQ:GILD) said the European Commission approved Stribild to treat HIV-1 infection in treatment-naïve adults or adults without mutations associated with resistance to the antiviral agents in the product. FDA approved the once-daily tablet comprising elvitegravir, cobicistat and Truvada emtricitabine/tenofovir for the indication last August. Gilead said it will launch Stribild immediately in the U.K. and Germany. ...